Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Prostate

Retrieve available abstracts of 522 articles:
HTML format



Single Articles


    June 2021
  1. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    PubMed     Abstract available


  2. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    PubMed     Abstract available


    May 2021
  3. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    PubMed     Abstract available


  4. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    PubMed     Abstract available


  5. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    PubMed     Abstract available


  6. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    PubMed     Abstract available


  7. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    PubMed     Abstract available


  8. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    PubMed     Abstract available


  9. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    PubMed     Abstract available


    April 2021
  10. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed     Abstract available


  11. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed     Abstract available


  12. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed     Abstract available


  13. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed     Abstract available


  14. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed     Abstract available


  15. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed     Abstract available


  16. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed     Abstract available


  17. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    PubMed     Abstract available


  18. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    PubMed     Abstract available


  19. LEDET EM, Burgess EF, Sokolova AO, Jaeger EB, et al
    Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Prostate. 2021 Apr 1. doi: 10.1002/pros.24123.
    PubMed     Abstract available


    March 2021
  20. SABOL RA, Ledet EM, Jaeger E, Hatton W, et al
    Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Prostate. 2021 Mar 24. doi: 10.1002/pros.24120.
    PubMed     Abstract available


  21. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    What are survivorship care plans failing to tell men after prostate cancer treatment?
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24116.
    PubMed     Abstract available


  22. GRAHAM LS, True LD, Gulati R, Schade GR, et al
    Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24118.
    PubMed     Abstract available


  23. LEHTO TK, Sturenberg C, Malen A, Erickson AM, et al
    Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24108.
    PubMed     Abstract available


  24. LIOTTI A, La Civita E, Cennamo M, Crocetto F, et al
    Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24117.
    PubMed     Abstract available


  25. ZHENG X, Xu H, Gong L, Cao D, et al
    Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation.
    Prostate. 2021 Mar 12. doi: 10.1002/pros.24113.
    PubMed     Abstract available


  26. ATEEQ B, Kunju LP, Carskadon SL, Pandey SK, et al
    Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Prostate. 2021 Mar 8. doi: 10.1002/pros.24111.
    PubMed    


    February 2021
  27. SHENDEROV E, Boudadi K, Fu W, Wang H, et al
    Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Prostate. 2021 Feb 26. doi: 10.1002/pros.24110.
    PubMed     Abstract available


  28. WETTSTEIN MS, David LA, Pazhepurackel C, Qureshi AA, et al
    Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
    Prostate. 2021 Feb 18. doi: 10.1002/pros.24105.
    PubMed     Abstract available


  29. TAO LJ, Pan XY, Wang JW, Zhang L, et al
    Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes prostate cancer progression by upregulating TGF-alpha expression.
    Prostate. 2021 Feb 8. doi: 10.1002/pros.24102.
    PubMed     Abstract available


    January 2021
  30. NAITO R, Kano H, Shimada T, Makino T, et al
    A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Prostate. 2021 Jan 25. doi: 10.1002/pros.24106.
    PubMed     Abstract available


  31. EMAM A, Hermann G, Attwood K, Ji W, et al
    Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
    Prostate. 2021 Jan 20. doi: 10.1002/pros.24089.
    PubMed     Abstract available


  32. VLACHOSTERGIOS PJ, Niaz MJ, Skafida M, Mosallaie SA, et al
    Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted beta-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jan 19. doi: 10.1002/pros.24104.
    PubMed     Abstract available


  33. LIU JM, Lin CC, Chen MF, Liu KL, et al
    Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
    Prostate. 2021 Jan 4. doi: 10.1002/pros.24096.
    PubMed     Abstract available


  34. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    PubMed     Abstract available


    December 2020
  35. IMAMURA R, Kitagawa S, Kubo T, Irie A, et al
    Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Prostate. 2020 Dec 24. doi: 10.1002/pros.24090.
    PubMed     Abstract available


  36. COUGHLIN SS, Vernon M, Klaassen Z, Tingen MS, et al
    Knowledge of prostate cancer among African American men: A systematic review.
    Prostate. 2020 Dec 23. doi: 10.1002/pros.24097.
    PubMed     Abstract available


  37. KAZUNO S, Fujimura T, Fujime M, Miura Y, et al
    O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.
    Prostate. 2020 Dec 21. doi: 10.1002/pros.24094.
    PubMed     Abstract available


  38. ZHANG Y, Mou Y, Liang C, Zhu S, et al
    Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
    Prostate. 2020 Dec 18. doi: 10.1002/pros.24092.
    PubMed     Abstract available


  39. ZHOU Y, Mai Z, Yan W, Chen Y, et al
    The characteristics and spatial distributions of prostate cancer in autopsy specimens.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24091.
    PubMed     Abstract available


  40. ZHANG Y, Guo Z, Du T, Chen J, et al
    Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24093.
    PubMed    


  41. SHEIKHBAHAEI S, Reyes DK, Rowe SP, Pienta KJ, et al
    CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer.
    Prostate. 2020 Dec 1. doi: 10.1002/pros.24088.
    PubMed     Abstract available


  42. GREENLAND NY, Cowan JE, Chan E, Carroll PR, et al
    Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
    Prostate. 2020;80:1421-1428.
    PubMed     Abstract available


  43. LI W, Bicak M, Sjoberg DD, Vertosick E, et al
    Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
    Prostate. 2020;80:1405-1412.
    PubMed     Abstract available


    November 2020
  44. SHIH HJ, Fang SC, An L, Shao YJ, et al
    Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.
    Prostate. 2020 Nov 5. doi: 10.1002/pros.24087.
    PubMed     Abstract available


  45. YAMOAH K, Lal P, Awasthi S, Naghavi AO, et al
    TMPRSS2-ERG fusion impact anterior tumor location in men with prostate cancer.
    Prostate. 2020 Nov 3. doi: 10.1002/pros.24086.
    PubMed     Abstract available


  46. DEEK M, Lilleby W, Vaage V, Hole KH, et al
    Impact of radiation dose on recurrence in high-risk prostate cancer patients.
    Prostate. 2020;80:1322-1327.
    PubMed     Abstract available


  47. BLACK MH, Li S, LaDuca H, Lo MT, et al
    Validation of a prostate cancer polygenic risk score.
    Prostate. 2020;80:1314-1321.
    PubMed     Abstract available


    October 2020
  48. JARRARD D, Filon M, Huang W, Havighurst T, et al
    A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
    Prostate. 2020 Oct 23. doi: 10.1002/pros.24076.
    PubMed     Abstract available


  49. YANG Y, Attwood K, Bshara W, Mohler JL, et al
    High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24068.
    PubMed     Abstract available


  50. MIYAHIRA AK, Soule HR
    The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24083.
    PubMed     Abstract available


  51. WASHINGTON SL 3RD, Cowan JE, Herlemann A, Zuniga KB, et al
    Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Prostate. 2020 Oct 19. doi: 10.1002/pros.24085.
    PubMed     Abstract available


  52. AMELOT A, Terrier LM, Le Nail LR, Cristini J, et al
    Spine metastasis in patients with prostate cancer: Survival prognosis assessment.
    Prostate. 2020 Oct 16. doi: 10.1002/pros.24084.
    PubMed     Abstract available


  53. IWAMOTO H, Izumi K, Shimada T, Kano H, et al
    Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
    Prostate. 2020 Oct 13. doi: 10.1002/pros.24082.
    PubMed     Abstract available


  54. DING Y, Lee M, Gao Y, Bu P, et al
    Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance.
    Prostate. 2020 Oct 6. doi: 10.1002/pros.24081.
    PubMed     Abstract available


  55. HERTZOG JR, Zhang Z, Bignan G, Connolly PJ, et al
    AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
    Prostate. 2020;80:1223-1232.
    PubMed     Abstract available


  56. MONTES M, MacKenzie L, McAllister MJ, Roseweir A, et al
    Determining the prognostic significance of IKKalpha in prostate cancer.
    Prostate. 2020;80:1188-1202.
    PubMed     Abstract available


    September 2020
  57. VICIER C, Ravi P, Kwak L, Werner L, et al
    Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Prostate. 2020 Sep 28. doi: 10.1002/pros.24079.
    PubMed     Abstract available


  58. OMRI N, Kamil M, Alexander K, Alexander K, et al
    Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Prostate. 2020 Sep 24. doi: 10.1002/pros.24078.
    PubMed     Abstract available


  59. LEE BS, Chu SY, Jung WJ, Jeong HJ, et al
    (18) F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
    Prostate. 2020 Sep 22. doi: 10.1002/pros.24062.
    PubMed     Abstract available


  60. VILSON FL, Li S, Brooks JD, Eisenberg ML, et al
    Sudden PSA rise to >/=20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
    Prostate. 2020 Sep 21. doi: 10.1002/pros.24075.
    PubMed     Abstract available


  61. HARSHMAN LC, Wang VX, Hamid AA, Santone G, et al
    Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Prostate. 2020 Sep 19. doi: 10.1002/pros.24074.
    PubMed     Abstract available


  62. NAITO Y, Kato M, Kawanishi H, Yuguchi Y, et al
    The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Prostate. 2020 Sep 11. doi: 10.1002/pros.24069.
    PubMed     Abstract available


  63. DUBEY B, Jackson M, Zeigler-Johnson C, Devarajan K, et al
    Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24067.
    PubMed     Abstract available


  64. ZHANG M, Wang Q, Sun X, Yin Q, et al
    beta2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24060.
    PubMed     Abstract available


  65. KAUR H, Samarska I, Lu J, Faisal F, et al
    Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Prostate. 2020;80:1012-1023.
    PubMed     Abstract available


  66. ANGEL PM, Spruill L, Jefferson M, Bethard JR, et al
    Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
    Prostate. 2020;80:1071-1086.
    PubMed     Abstract available


    August 2020
  67. MIYAHIRA AK, Pienta KJ, Babich JW, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
    Prostate. 2020 Aug 31. doi: 10.1002/pros.24056.
    PubMed     Abstract available


  68. MCALLISTER M, Constancio V, Patek S, Gan H, et al
    Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer.
    Prostate. 2020 Aug 26. doi: 10.1002/pros.24064.
    PubMed     Abstract available


  69. WIGGINS EK, Oyekunle T, Howard LE, Markt SC, et al
    Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.
    Prostate. 2020 Aug 24. doi: 10.1002/pros.24052.
    PubMed     Abstract available


  70. LIU W, Hou J, Petkewicz J, Na R, et al
    Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
    Prostate. 2020 Aug 17. doi: 10.1002/pros.24057.
    PubMed     Abstract available


  71. SHORE ND, Drake CG, Lin DW, Ryan CJ, et al
    Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
    Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
    PubMed     Abstract available


  72. DI BELLA CM, Howard LE, Oyekunle T, De Hoedt AM, et al
    Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
    Prostate. 2020 Aug 7. doi: 10.1002/pros.24054.
    PubMed     Abstract available


  73. SIMONS BW, Dalrymple S, Rosen M, Zheng L, et al
    A hemi-spleen injection model of liver metastasis for prostate cancer.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24055.
    PubMed     Abstract available


  74. NAEEM A, Dakshanamurthy S, Walthieu H, Parasido E, et al
    Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24050.
    PubMed     Abstract available


    July 2020
  75. AHMED ME, Andrews JR, Alamiri J, Higa J, et al
    Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
    Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.
    PubMed     Abstract available


  76. NANDA JS, Awadallah WN, Kohrt SE, Popovics P, et al
    Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Prostate. 2020 Jul 21. doi: 10.1002/pros.24019.
    PubMed     Abstract available


  77. FERRARI MG, Ganaie AA, Shabenah A, Mansini AP, et al
    Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients.
    Prostate. 2020 Jul 20. doi: 10.1002/pros.24018.
    PubMed     Abstract available


  78. DEE EC, Nezolosky MD, Chipidza FE, Arega MA, et al
    Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
    Prostate. 2020 Jul 13. doi: 10.1002/pros.24041.
    PubMed     Abstract available


  79. ABUDUREXITI M, Zhu W, Wang Y, Wang J, et al
    Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Prostate. 2020 Jul 10. doi: 10.1002/pros.24027.
    PubMed     Abstract available


  80. ERICKSON AM, Lokman U, Lahdensuo K, Tornberg S, et al
    PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
    Prostate. 2020 Jul 7. doi: 10.1002/pros.24040.
    PubMed     Abstract available


  81. ZHAN B, Huang L, Chen Y, Ye W, et al
    miR-196a-mediated downregulation of p27(kip1) protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24036.
    PubMed     Abstract available


  82. FEDERER-GSPONER JR, Muller DC, Zellweger T, Eggimann M, et al
    Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24039.
    PubMed     Abstract available


  83. QIN C, Sheng Z, Huang X, Tang J, et al
    Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24042.
    PubMed     Abstract available


  84. BONK S, Kluth M, Jansen K, Hube-Magg C, et al
    Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24038.
    PubMed     Abstract available


  85. TANG M, Gao S, Zhang L, Liu B, et al
    Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Prostate. 2020;80:742-752.
    PubMed     Abstract available


  86. RINELLA L, Pizzo B, Frairia R, Delsedime L, et al
    Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
    Prostate. 2020 Jul 1. doi: 10.1002/pros.24037.
    PubMed     Abstract available


    June 2020
  87. CHEN Y, Li X, Mamouni K, Yang Y, et al
    Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer.
    Prostate. 2020 Jun 19. doi: 10.1002/pros.24032.
    PubMed     Abstract available


  88. MAESHIGE N, Kitagawa K, Yamasaki S, Ishii A, et al
    Can ultrasound irradiation be a therapeutic option for prostate cancer?
    Prostate. 2020 Jun 18. doi: 10.1002/pros.24030.
    PubMed     Abstract available


  89. BEGEMANN D, Wang Y, Yang W, Kyprianou N, et al
    Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Prostate. 2020 Jun 16. doi: 10.1002/pros.24015.
    PubMed     Abstract available


  90. WANG K, Chen Z, Shi J, Feng Y, et al
    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
    Prostate. 2020 Jun 15. doi: 10.1002/pros.24029.
    PubMed     Abstract available


  91. TAYLOR RA, Farrelly SG, Clark AK, Watt MJ, et al
    Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice.
    Prostate. 2020 Jun 10. doi: 10.1002/pros.24024.
    PubMed     Abstract available


  92. ELHODAKY M, Hong LK, Kadkol S, Diamond AM, et al
    Selenium-binding protein 1 alters energy metabolism in prostate cancer cells.
    Prostate. 2020 Jun 8. doi: 10.1002/pros.24028.
    PubMed     Abstract available


  93. CHADID S, Barber JR, Nelson WG, Gurel B, et al
    The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24023.
    PubMed     Abstract available


  94. CARSON JJK, Di Lena MA, Berman DM, Siemens DR, et al
    Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24025.
    PubMed     Abstract available


  95. RII J, Sakamoto S, Yamada Y, Takeshita N, et al
    Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Prostate. 2020 Jun 5. doi: 10.1002/pros.24016.
    PubMed     Abstract available


  96. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2020;80:727.
    PubMed    


  97. OJALILL M, Virtanen N, Rappu P, Siljamaki E, et al
    Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins.
    Prostate. 2020;80:715-726.
    PubMed     Abstract available


  98. ITSUMI M, Shiota M, Sekino Y, Ushijima M, et al
    High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
    Prostate. 2020 Jun 1. doi: 10.1002/pros.24022.
    PubMed     Abstract available


  99. ELSHAFAE SM, Dirksen WP, Alasonyalilar-Demirer A, Breitbach J, et al
    Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Prostate. 2020;80:698-714.
    PubMed     Abstract available


  100. PALANGMONTHIP W, Wu R, Tarima S, Bobholz SA, et al
    Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
    Prostate. 2020;80:687-697.
    PubMed     Abstract available


    May 2020
  101. LINDER A, Larsson K, Welen K, Damber JE, et al
    RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Prostate. 2020 May 25. doi: 10.1002/pros.23994.
    PubMed     Abstract available


  102. TABEI T, Taguri M, Sakai N, Koh H, et al
    Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
    Prostate. 2020 May 20. doi: 10.1002/pros.23997.
    PubMed     Abstract available


  103. SHI X, Sun J, Li H, Lin H, et al
    Antitumor efficacy of interferon-gamma-modified exosomal vaccine in prostate cancer.
    Prostate. 2020 May 19. doi: 10.1002/pros.23996.
    PubMed     Abstract available


  104. HOU Y, Li H, Huo W
    THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
    Prostate. 2020 May 18. doi: 10.1002/pros.23989.
    PubMed     Abstract available


  105. LIU Z, Murphy SF, Huang J, Zhao L, et al
    A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Prostate. 2020 May 14. doi: 10.1002/pros.23993.
    PubMed     Abstract available


  106. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study.
    Prostate. 2020 May 5. doi: 10.1002/pros.23991.
    PubMed     Abstract available


  107. LIU S, Liu F, Zhang B, Yan P, et al
    CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion.
    Prostate. 2020 May 1. doi: 10.1002/pros.23990.
    PubMed     Abstract available


  108. SU X, Long Q, Bo J, Shi Y, et al
    Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
    Prostate. 2020;80:508-517.
    PubMed     Abstract available


  109. GLEAVE AM, Ci X, Lin D, Wang Y, et al
    A synopsis of prostate organoid methodologies, applications, and limitations.
    Prostate. 2020;80:518-526.
    PubMed     Abstract available


  110. GREENLAND NY, Cowan JE, Zhang L, Carroll PR, et al
    Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Prostate. 2020;80:653-659.
    PubMed     Abstract available


    April 2020
  111. SEBBEN M, Tafuri A, Porcaro AB, Artibani W, et al
    Response to: Bando et al. Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histological and molecular analyses.
    Prostate. 2020 Apr 23. doi: 10.1002/pros.23987.
    PubMed    


  112. LI X, Jiao M, Hu J, Qi M, et al
    miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Prostate. 2020 Apr 15. doi: 10.1002/pros.23979.
    PubMed     Abstract available


  113. CHENG Y, Wang D, Jiang J, Huang W, et al
    Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Prostate. 2020 Apr 13. doi: 10.1002/pros.23976.
    PubMed     Abstract available


    March 2020
  114. CARIGNAN D, Lessard T, Villeneuve L, Desjardins S, et al
    DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
    Prostate. 2020 Mar 23. doi: 10.1002/pros.23975.
    PubMed     Abstract available


  115. DERLIN T, Sommerlath Sohns JM, Schmuck S, Henkenberens C, et al
    Influence of short-term dexamethasone on the efficacy of (177) Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2020 Mar 18. doi: 10.1002/pros.23974.
    PubMed     Abstract available


  116. LIU W, Zhang Y, Wei S, Bae S, et al
    A CD24-p53 axis contributes to African American prostate cancer disparities.
    Prostate. 2020 Mar 13. doi: 10.1002/pros.23973.
    PubMed     Abstract available


  117. ZHANG J, Kim S, Li L, Kemp CJ, et al
    Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Prostate. 2020 Mar 12. doi: 10.1002/pros.23972.
    PubMed     Abstract available


  118. CONNELL SP, O'Reilly E, Tuzova A, Webb M, et al
    Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
    Prostate. 2020 Mar 9. doi: 10.1002/pros.23968.
    PubMed     Abstract available


  119. SEO HK, Lee SJ, Kwon WA, Jeong KC, et al
    Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
    Prostate. 2020 Mar 5. doi: 10.1002/pros.23946.
    PubMed     Abstract available


  120. YAMADA Y, Sakamoto S, Rii J, Yamamoto S, et al
    Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2020 Mar 5. doi: 10.1002/pros.23969.
    PubMed     Abstract available


  121. SHORE ND, Antonarakis ES, Cookson MS, Crawford ED, et al
    Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
    Prostate. 2020 Mar 4. doi: 10.1002/pros.23967.
    PubMed     Abstract available


  122. LEU WJ, Wang CT, Hsu JL, Chen IS, et al
    Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na(+) /K(+) -ATPase internalization and tubulin acetylation.
    Prostate. 2020;80:305-318.
    PubMed     Abstract available


  123. WU Z, Wang K, Yang Z, Pascal LE, et al
    A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function.
    Prostate. 2020;80:319-328.
    PubMed     Abstract available


    February 2020
  124. RUBIO-BRIONES J, Borque-Fernando A, Esteban LM, Mascaros JM, et al
    Validation of a 2-gene mRNA urine test for the detection of >/=GG2 prostate cancer in an opportunistic screening population.
    Prostate. 2020 Feb 20. doi: 10.1002/pros.23964.
    PubMed     Abstract available


  125. BRADY L, Gil da Costa RM, Coleman IM, Matson CK, et al
    A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments.
    Prostate. 2020 Feb 18. doi: 10.1002/pros.23963.
    PubMed     Abstract available


  126. MARLIN R, Creoff M, Merle S, Jean-Marie-Flore M, et al
    Mutation HOXB13 c.853delT in Martinican prostate cancer patients.
    Prostate. 2020 Feb 10. doi: 10.1002/pros.23960.
    PubMed     Abstract available


  127. GREENBERG S, Slager S, Neil BO, Cooney K, et al
    What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
    Prostate. 2020 Feb 6. doi: 10.1002/pros.23959.
    PubMed     Abstract available


  128. YAMADA Y, Sakamoto S, Rii J, Yamamoto S, et al
    How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: A retrospective multicenter cohort study.
    Prostate. 2020 Feb 3. doi: 10.1002/pros.23958.
    PubMed     Abstract available


  129. YEON A, Wang Y, Su S, Lo EM, et al
    Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100.
    Prostate. 2020 Feb 3. doi: 10.1002/pros.23957.
    PubMed     Abstract available


  130. ERDEM S, Verep S, Bagbudar S, Ozluk Y, et al
    The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
    Prostate. 2020;80:225-234.
    PubMed     Abstract available


  131. FAGERLAND ST, Hill DK, van Wamel A, de Lange Davies C, et al
    Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
    Prostate. 2020;80:186-197.
    PubMed     Abstract available


  132. TAYLOR AS, Morgan TM, Wallington DG, Chinnaiyan AM, et al
    Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Prostate. 2020;80:146-152.
    PubMed     Abstract available


  133. THOMAS-JARDIN SE, Dahl H, Kanchwala MS, Ha F, et al
    RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Prostate. 2020;80:133-145.
    PubMed     Abstract available


  134. WANG R, Lewis MS, Lyu J, Zhau HE, et al
    Cancer-stromal cell fusion as revealed by fluorescence protein tracking.
    Prostate. 2020;80:274-283.
    PubMed     Abstract available


    January 2020
  135. VENUGOPAL SV, Caggia S, Gambrell-Sanders D, Khan SA, et al
    Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Prostate. 2020 Jan 29. doi: 10.1002/pros.23956.
    PubMed     Abstract available


  136. MARKOWSKI MC, Shenderov E, Eisenberger MA, Kachhap S, et al
    Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    Prostate. 2020 Jan 23. doi: 10.1002/pros.23955.
    PubMed     Abstract available


  137. XING Z, Li S, Liu Z, Zhang C, et al
    CTCF-induced upregulation of HOXA11-AS facilitates cell proliferation and migration by targeting miR-518b/ACTN4 axis in prostate cancer.
    Prostate. 2020 Jan 23. doi: 10.1002/pros.23953.
    PubMed     Abstract available


  138. WENJING H, Shao Y, Yu Y, Huang W, et al
    Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
    Prostate. 2020 Jan 22. doi: 10.1002/pros.23951.
    PubMed     Abstract available


  139. LI X, Huang H, Zhang J, Jiang F, et al
    A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Prostate. 2020 Jan 21. doi: 10.1002/pros.23952.
    PubMed     Abstract available


  140. ANDREWS JR, Ahmed ME, Karnes RJ, Kwon E, et al
    Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
    Prostate. 2020 Jan 13. doi: 10.1002/pros.23954.
    PubMed     Abstract available


  141. SONG Q, Qin S, Pascal LE, Zou C, et al
    SIRPB1 promotes prostate cancer cell proliferation via Akt activation.
    Prostate. 2020 Jan 6. doi: 10.1002/pros.23950.
    PubMed     Abstract available


  142. HAWLEY JE, Pan S, Figg WD, Lopez-Bujanda ZA, et al
    Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
    Prostate. 2020 Jan 3. doi: 10.1002/pros.23948.
    PubMed     Abstract available


  143. BANDO Y, Hinata N, Terakawa T, Furukawa J, et al
    Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histopathological and molecular analyses.
    Prostate. 2020 Jan 3. doi: 10.1002/pros.23949.
    PubMed     Abstract available


    December 2019
  144. HOSSAIN A, Arimura H, Kinoshita F, Ninomiya K, et al
    Automated approach for estimation of grade groups for prostate cancer based on histological image feature analysis.
    Prostate. 2019 Dec 23. doi: 10.1002/pros.23943.
    PubMed     Abstract available


  145. MOLLARD P, Perrot E, Blanchet P, Brureau L, et al
    Overall, specific, and metastasis-free survival of Afro-Caribbean men with pathological Gleason 6 prostate cancer.
    Prostate. 2019 Dec 23. doi: 10.1002/pros.23947.
    PubMed     Abstract available


  146. KATO M, Hirakawa A, Kobayashi Y, Yamamoto A, et al
    Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Prostate. 2019 Dec 20. doi: 10.1002/pros.23942.
    PubMed     Abstract available


  147. CHEN X, Liu J, Cheng L, Li C, et al
    Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Prostate. 2019 Dec 19. doi: 10.1002/pros.23939.
    PubMed     Abstract available


  148. GRUBER M, Handle F, Culig Z
    The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
    Prostate. 2019 Dec 13. doi: 10.1002/pros.23940.
    PubMed     Abstract available


  149. MIYAHIRA AK, Sharp A, Ellis L, Jones J, et al
    Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2019 Dec 11. doi: 10.1002/pros.23934.
    PubMed     Abstract available


  150. ANDO K, Sakamoto S, Takeshita N, Fujimoto A, et al
    Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel.
    Prostate. 2019 Dec 9. doi: 10.1002/pros.23938.
    PubMed     Abstract available


  151. YLITALO EB, Thysell E, Thellenberg-Karlsson C, Lundholm M, et al
    Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Prostate. 2019 Dec 4. doi: 10.1002/pros.23935.
    PubMed     Abstract available


  152. PARDY L, Rosati R, Soave C, Huang Y, et al
    The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.
    Prostate. 2019 Dec 3. doi: 10.1002/pros.23932.
    PubMed     Abstract available


  153. FERNANDEZ-CONEJO G, Hernandez V, Guijarro A, de la Pena E, et al
    Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series.
    Prostate. 2019 Dec 2. doi: 10.1002/pros.23933.
    PubMed     Abstract available


    November 2019
  154. ELIX CC, Salgia MM, Otto-Duessel M, Copeland BT, et al
    Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.
    Prostate. 2019 Nov 26. doi: 10.1002/pros.23928.
    PubMed     Abstract available


  155. VICKMAN RE, Broman MM, Lanman NA, Franco OE, et al
    Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment.
    Prostate. 2019 Nov 25. doi: 10.1002/pros.23929.
    PubMed     Abstract available


  156. PETRYLAK DP, Vogelzang NJ, Chatta K, Fleming MT, et al
    PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
    Prostate. 2019 Nov 19. doi: 10.1002/pros.23922.
    PubMed     Abstract available


  157. BADAL S, Aiken W, Morrison B, Valentine H, et al
    Disparities in prostate cancer incidence and mortality rates: Solvable or not?
    Prostate. 2019 Nov 8. doi: 10.1002/pros.23923.
    PubMed     Abstract available


  158. LEDET EM, Antonarakis ES, Isaacs WB, Lotan TL, et al
    Germline BLM mutations and metastatic prostate cancer.
    Prostate. 2019 Nov 5. doi: 10.1002/pros.23924.
    PubMed     Abstract available


  159. FENG Y, Jaratlerdsiri W, Patrick SM, Lyons RJ, et al
    Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men.
    Prostate. 2019;79:1731-1738.
    PubMed     Abstract available


    October 2019
  160. KIM M, Kim JK, Ye C, Lee H, et al
    Clinical and pathologic characteristics of familial prostate cancer in Asian population.
    Prostate. 2019 Oct 30. doi: 10.1002/pros.23917.
    PubMed     Abstract available


  161. CARBONETTI G, Converso C, Clement T, Wang C, et al
    Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Prostate. 2019 Oct 29. doi: 10.1002/pros.23921.
    PubMed     Abstract available


  162. YU H, Shi Z, Lin X, Bao Q, et al
    Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment.
    Prostate. 2019 Oct 21. doi: 10.1002/pros.23920.
    PubMed     Abstract available


  163. SHAO L, Kahraman N, Yan G, Wang J, et al
    Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
    Prostate. 2019 Oct 15. doi: 10.1002/pros.23918.
    PubMed     Abstract available


  164. GRUBMULLER B, Rasul S, Baltzer P, Fajkovic H, et al
    Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
    Prostate. 2019 Oct 15. doi: 10.1002/pros.23919.
    PubMed     Abstract available


  165. ASSEL MJ, Ulmert HD, Karnes RJ, Boorjian SA, et al
    Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
    Prostate. 2019 Oct 11. doi: 10.1002/pros.23916.
    PubMed     Abstract available


  166. LU Z, Williamson SR, Carskadon S, Arachchige PD, et al
    Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Prostate. 2019 Oct 4. doi: 10.1002/pros.23914.
    PubMed     Abstract available


  167. YORDANOVA A, Linden P, Hauser S, Feldmann G, et al
    The value of tumor markers in men with metastatic prostate cancer undergoing [(177) Lu]Lu-PSMA therapy.
    Prostate. 2019 Oct 3. doi: 10.1002/pros.23912.
    PubMed     Abstract available


  168. CACKOWSKI FC, Wang Y, Decker JT, Sifuentes C, et al
    Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.
    Prostate. 2019;79:1715-1727.
    PubMed     Abstract available


  169. UZUN H, Arpa M
    The impact of diurnal variation of PSA on timing of measurement in prostate biopsy.
    Prostate. 2019;79:1666-1672.
    PubMed     Abstract available


    September 2019
  170. KVALE R, Myklebust TA, Fossa SD, Aas K, et al
    Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients.
    Prostate. 2019 Sep 30. doi: 10.1002/pros.23911.
    PubMed     Abstract available


  171. PREISSER F, Coxilha G, Heinze A, Oh S, et al
    Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer.
    Prostate. 2019 Sep 25. doi: 10.1002/pros.23908.
    PubMed     Abstract available


  172. LOW JY, Sirajuddin P, Moubarek M, Agarwal S, et al
    Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
    Prostate. 2019 Sep 16. doi: 10.1002/pros.23909.
    PubMed     Abstract available


  173. ZHU Z, Hong Y, Zhang F, An L, et al
    Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.
    Prostate. 2019 Sep 11. doi: 10.1002/pros.23907.
    PubMed     Abstract available


  174. VELLKY JE, Bauman TM, Ricke EA, Huang W, et al
    Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.
    Prostate. 2019 Sep 10. doi: 10.1002/pros.23906.
    PubMed     Abstract available


  175. ROBERTO D, Selvarajah S, Park PC, Berman D, et al
    Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
    Prostate. 2019 Sep 10. doi: 10.1002/pros.23903.
    PubMed     Abstract available


  176. GEORGE DJ, Halabi S, Healy P, Barak I, et al
    Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    Prostate. 2019 Sep 9. doi: 10.1002/pros.23899.
    PubMed     Abstract available


  177. XU Y, Huang D, Wu Y, Ye D, et al
    Family history is significantly associated with prostate cancer and its early onset in Chinese population.
    Prostate. 2019 Sep 9. doi: 10.1002/pros.23900.
    PubMed     Abstract available


  178. JANG WS, Koh DH, Kim J, Lee JS, et al
    The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer.
    Prostate. 2019 Sep 4. doi: 10.1002/pros.23905.
    PubMed     Abstract available


  179. PERROUIN-VERBE MA, Schoentgen N, Talagas M, Garlantezec R, et al
    Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.
    Prostate. 2019 Sep 2. doi: 10.1002/pros.23904.
    PubMed     Abstract available


  180. JONCAS FH, Lucien F, Rouleau M, Morin F, et al
    Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients.
    Prostate. 2019 Sep 2. doi: 10.1002/pros.23901.
    PubMed     Abstract available


  181. FU S, Wan X, Du C, Wang H, et al
    A novel fluorescent probe for the early detection of prostate cancer based on endogenous zinc sensing.
    Prostate. 2019;79:1378-1385.
    PubMed     Abstract available


  182. ROUSSEAU C, Le Thiec M, Ferrer L, Rusu D, et al
    Preliminary results of a (68) Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
    Prostate. 2019;79:1514-1522.
    PubMed     Abstract available


  183. MIYAZAWA Y, Sekine Y, Shimizu N, Takezawa Y, et al
    An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
    Prostate. 2019;79:1462-1470.
    PubMed     Abstract available


  184. METZGER AL, Abel S, Wegner RE, Fuhrer R, et al
    Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
    Prostate. 2019;79:1457-1461.
    PubMed     Abstract available


  185. KRANZBUHLER B, Salemi S, Umbricht CA, Deberle LM, et al
    Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of (177) Lu-PSMA-617 in LNCaP cells.
    Prostate. 2019;79:1450-1456.
    PubMed     Abstract available


  186. AMEND SR, Torga G, Lin KC, Kostecka LG, et al
    Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance.
    Prostate. 2019;79:1489-1497.
    PubMed     Abstract available


  187. HUANG SY, Huang GJ, Hsieh PF, Wu HC, et al
    Osajin displays potential antiprostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression.
    Prostate. 2019;79:1543-1552.
    PubMed     Abstract available


    August 2019
  188. SHISHODIA G, Koul S, Koul HK
    Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling.
    Prostate. 2019 Aug 26. doi: 10.1002/pros.23898.
    PubMed     Abstract available


  189. SARTOR O, Heinrich D, Mariados N, Mendez Vidal MJ, et al
    Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Prostate. 2019 Aug 23. doi: 10.1002/pros.23893.
    PubMed     Abstract available


  190. PATEL PG, Wessel T, Kawashima A, Okello JBA, et al
    A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23895.
    PubMed     Abstract available


  191. WU T, Zhao J, Liu Z, Shen P, et al
    Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23892.
    PubMed     Abstract available


  192. MADUEKE I, Hu WY, Hu D, Swanson SM, et al
    The role of WNT10B in normal prostate gland development and prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23894.
    PubMed     Abstract available


  193. ZHAO C, Zhang W, Zhu X, Xu Y, et al
    TWIST2: A new candidate tumor suppressor in prostate cancer.
    Prostate. 2019 Aug 21. doi: 10.1002/pros.23889.
    PubMed     Abstract available


  194. WATANABE M, Kanao K, Suzuki S, Muramatsu H, et al
    Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
    Prostate. 2019 Aug 7. doi: 10.1002/pros.23890.
    PubMed     Abstract available


  195. SHENDEROV E, Isaacsson Velho P, Awan AH, Wang H, et al
    Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
    Prostate. 2019 Aug 7. doi: 10.1002/pros.23881.
    PubMed     Abstract available


  196. MEUNIER ME, Tantot J, Neuzillet Y, Ghoneim TP, et al
    Grade groups at diagnosis in African Caribbean men with prostate cancer: Results of a comparative study.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23888.
    PubMed     Abstract available


  197. KAIPAINEN A, Zhang A, Gil da Costa RM, Lucas J, et al
    Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23874.
    PubMed     Abstract available


  198. EICH ML, Chandrashekar DS, Rodriguez Pen A MDC, Robinson AD, et al
    Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23887.
    PubMed     Abstract available


  199. WANG J, Xu W, Mierxiati A, Huang Y, et al
    Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23878.
    PubMed     Abstract available


  200. TANAKA M, Kimura T, Iwamura Y, Enei Y, et al
    No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23884.
    PubMed     Abstract available


  201. CHENG A, Zhao S, FitzGerald LM, Wright JL, et al
    A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
    Prostate. 2019 Aug 2. doi: 10.1002/pros.23882.
    PubMed     Abstract available


  202. PILLING AB, Hwang C
    Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Prostate. 2019;79:1347-1359.
    PubMed     Abstract available


  203. YANG T, An Z, Zhang C, Wang Z, et al
    hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.
    Prostate. 2019;79:1199-1210.
    PubMed     Abstract available


  204. LOLLI C, De Lisi D, Conteduca V, Gurioli G, et al
    Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2019;79:1211-1220.
    PubMed     Abstract available


  205. PEIFFER LB, Poynton SL, Ernst SE, Hicks JL, et al
    Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis.
    Prostate. 2019;79:1316-1325.
    PubMed     Abstract available


  206. DONG F, Yang P, Wang R, Sun W, et al
    Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
    Prostate. 2019;79:1284-1293.
    PubMed     Abstract available


  207. YANG J, Broman MM, Cooper PO, Lanman NA, et al
    Distinct expression patterns of SULT2B1b in human prostate epithelium.
    Prostate. 2019;79:1256-1266.
    PubMed     Abstract available


  208. SHAH RB, Shore KT, Yoon J, Mendrinos S, et al
    PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Prostate. 2019;79:1267-1273.
    PubMed     Abstract available


    July 2019
  209. PALLER CJ, Piana D, Eshleman JR, Riel S, et al
    A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    Prostate. 2019 Jul 30. doi: 10.1002/pros.23883.
    PubMed     Abstract available


  210. HELLSTEN R, Lilljebjorn L, Johansson M, Leandersson K, et al
    The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
    Prostate. 2019 Jul 26. doi: 10.1002/pros.23885.
    PubMed     Abstract available


  211. SILVESTRI R, Pucci P, Venalainen E, Matheou C, et al
    T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23879.
    PubMed     Abstract available


  212. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23861.
    PubMed     Abstract available


  213. MIYAHIRA AK, Soule HR
    The 25th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23872.
    PubMed     Abstract available


  214. KAWADA T
    RE: Joentausta et al. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
    Prostate. 2019 Jul 23. doi: 10.1002/pros.23862.
    PubMed    


  215. ZHAO J, Zhang M, Liu J, Liu Z, et al
    AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Prostate. 2019 Jul 11. doi: 10.1002/pros.23875.
    PubMed     Abstract available


  216. NAM RK, Benatar T, Wallis CJD, Kobylecky E, et al
    MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23871.
    PubMed     Abstract available


  217. VEREP S, Erdem S, Ozluk Y, Kilicaslan I, et al
    The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23873.
    PubMed     Abstract available


  218. BLOM S, Erickson A, Ostman A, Rannikko A, et al
    Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23867.
    PubMed     Abstract available


  219. WANG D, Wan X, Zhang Y, Kong Z, et al
    A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23840.
    PubMed     Abstract available


  220. HU WY, Xu L, Chen B, Ou S, et al
    Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
    Prostate. 2019;79:1166-1179.
    PubMed     Abstract available


  221. SHIOTA M, Ushijima M, Imada K, Kashiwagi E, et al
    Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
    Prostate. 2019;79:1147-1155.
    PubMed     Abstract available


  222. ROGERS O, Yen H, Solomon A, Drake C, et al
    An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response.
    Prostate. 2019;79:1071-1078.
    PubMed     Abstract available


  223. YU H, Shi Z, Wu Y, Wang CH, et al
    Concept and benchmarks for assessing narrow-sense validity of genetic risk score values.
    Prostate. 2019;79:1099-1105.
    PubMed     Abstract available


  224. KATO M, Hirakawa A, Kobayashi Y Ms, Yamamoto A, et al
    The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Prostate. 2019;79:1065-1070.
    PubMed     Abstract available


    June 2019
  225. JOENTAUSTA RM, Murtola TJ
    Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
    Prostate. 2019 Jun 24. doi: 10.1002/pros.23870.
    PubMed    


  226. KNUUTTILA E, Riikonen J, Syvala H, Auriola S, et al
    Access and concentrations of atorvastatin in the prostate in men with prostate cancer.
    Prostate. 2019 Jun 24. doi: 10.1002/pros.23863.
    PubMed     Abstract available


  227. UGGE H, Downer MK, Carlsson J, Bowden M, et al
    Circulating inflammation markers and prostate cancer.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23842.
    PubMed     Abstract available


  228. LEE MS, Lee J, Kim YM, Lee H, et al
    The metastasis suppressor CD82/KAI1 represses the TGF-beta 1 and Wnt signalings inducing epithelial-to-mesenchymal transition linked to invasiveness of prostate cancer cells.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23837.
    PubMed     Abstract available


  229. PORTER LH, Lawrence MG, Wang H, Clark AK, et al
    Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23839.
    PubMed     Abstract available


  230. YU W, Li J, Wang Q, Wang B, et al
    Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
    Prostate. 2019 Jun 18. doi: 10.1002/pros.23838.
    PubMed     Abstract available


  231. TEPLY BA, Qiu F, Antonarakis ES, Carducci MA, et al
    Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
    Prostate. 2019;79:929-933.
    PubMed     Abstract available


  232. BAUMANN B, Lugli G, Gao S, Zenner M, et al
    High levels of PIWI-interacting RNAs are present in the small RNA landscape of prostate epithelium from vitamin D clinical trial specimens.
    Prostate. 2019;79:840-855.
    PubMed     Abstract available


  233. KIM S, Yang X, Yin A, Zha J, et al
    Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
    Prostate. 2019;79:896-908.
    PubMed     Abstract available


  234. ZHANG P, Lu Y, Kong Z, Zhang Y, et al
    Androgen-responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1.
    Prostate. 2019;79:994-1006.
    PubMed     Abstract available


  235. AARON-BROOKS LM, Sasaki T, Vickman RE, Wei L, et al
    Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse.
    Prostate. 2019;79:980-993.
    PubMed     Abstract available


  236. NICKKHOLGH B, Sittadjody S, Ordonez K, Rothberg MB, et al
    Protein kinase D1 induces G1-phase cell-cycle arrest independent of Checkpoint kinases by phosphorylating Cell Division Cycle Phosphatase 25.
    Prostate. 2019;79:1053-1058.
    PubMed     Abstract available


    May 2019
  237. JIAO M, Qi M, Zhang F, Hu J, et al
    CUL4B regulates cancer stem-like traits of prostate cancer cells by targeting BMI1 via miR200b/c.
    Prostate. 2019 May 21. doi: 10.1002/pros.23835.
    PubMed     Abstract available


  238. WONG M, Bierman Y, Pettaway C, Kittles R, et al
    Comparative analysis of p16 expression among African American and European American prostate cancer patients.
    Prostate. 2019 May 21. doi: 10.1002/pros.23833.
    PubMed     Abstract available


  239. WU X, Scott H, Carlsson SV, Sjoberg DD, et al
    Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.
    Prostate. 2019 May 18. doi: 10.1002/pros.23817.
    PubMed     Abstract available


  240. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2019 May 18. doi: 10.1002/pros.23836.
    PubMed     Abstract available


  241. BLACKBURN J, Vecchiarelli S, Heyer EE, Patrick SM, et al
    TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
    Prostate. 2019 May 15. doi: 10.1002/pros.23823.
    PubMed     Abstract available


  242. HERNANDEZ-LLODRA S, Segales L, Safont A, Juanpere N, et al
    SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
    Prostate. 2019 May 15. doi: 10.1002/pros.23830.
    PubMed     Abstract available


  243. RAMAKRISHNAN S, Steck SE, Arab L, Zhang H, et al
    Association among plasma 1,25(OH)2 D, ratio of 1,25(OH)2 D to 25(OH)D, and prostate cancer aggressiveness.
    Prostate. 2019 May 11. doi: 10.1002/pros.23824.
    PubMed     Abstract available


  244. HAN IH, Kim JH, Jang KS, Ryu JS, et al
    Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cells.
    Prostate. 2019 May 2. doi: 10.1002/pros.23826.
    PubMed     Abstract available


  245. KRYVENKO ON, Wang Y, Sadasivan S, Gupta NS, et al
    Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy.
    Prostate. 2019 May 2. doi: 10.1002/pros.23820.
    PubMed     Abstract available


  246. MCNAMARA MA, Oyekunle T, Chin BB, Oldan J, et al
    Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    Prostate. 2019 May 2. doi: 10.1002/pros.23822.
    PubMed     Abstract available


  247. KURUL NO, Ates F, Yilmaz I, Narli G, et al
    The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
    Prostate. 2019 May 2. doi: 10.1002/pros.23825.
    PubMed     Abstract available



  248. Re: Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. The Prostate. 2019;1-7.
    Prostate. 2019;79:813-814.
    PubMed    



  249. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J, Rayford W. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 2004;60(2):141-152.
    Prostate. 2019;79:815.
    PubMed    


  250. PADDA RS, Deng FK, Brett SI, Biggs CN, et al
    Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
    Prostate. 2019;79:592-603.
    PubMed     Abstract available


  251. SIMONS BW, Turtle NF, Ulmert DH, Abou DS, et al
    PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool.
    Prostate. 2019;79:678-685.
    PubMed     Abstract available


  252. KOLEVA M, Dikov D, Belovejdov V, Sarafian V, et al
    Expression of MUC1 in eosinophilic metaplasia of the prostate.
    Prostate. 2019;79:622-627.
    PubMed     Abstract available


    April 2019
  253. DUIJVESZ D, Rodriguez-Blanco G, Hoogland AM, Verhoef EI, et al
    Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23813.
    PubMed     Abstract available


  254. XIANG P, Jin S, Yang Y, Sheng J, et al
    Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23810.
    PubMed     Abstract available


  255. MOLL JM, Kumagai J, van Royen ME, Teubel WJ, et al
    A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23799.
    PubMed     Abstract available


  256. YILMAZ B, Turkay R, Colakoglu Y, Baytekin HF, et al
    Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Prostate. 2019 Apr 23. doi: 10.1002/pros.23812.
    PubMed     Abstract available


  257. VIDOTTO T, Saggioro FP, Jamaspishvili T, Chesca DL, et al
    PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Prostate. 2019 Apr 18. doi: 10.1002/pros.23808.
    PubMed     Abstract available


  258. HONDA M, Kimura T, Kamata Y, Tashiro K, et al
    Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Prostate. 2019 Apr 18. doi: 10.1002/pros.23816.
    PubMed     Abstract available


  259. KIM S, Zhang Y, Tang S, Qin C, et al
    Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice.
    Prostate. 2019 Apr 8. doi: 10.1002/pros.23802.
    PubMed     Abstract available


  260. MCDONALD AC, Vira M, Walter V, Shen J, et al
    Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
    Prostate. 2019 Apr 8. doi: 10.1002/pros.23803.
    PubMed     Abstract available


  261. GANG X, Xuan L, Zhao X, Lv Y, et al
    Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Prostate. 2019 Apr 7. doi: 10.1002/pros.23793.
    PubMed     Abstract available


    March 2019
  262. KRISTIANSEN A, Bergstrom R, Delahunt B, Samaratunga H, et al
    Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer.
    Prostate. 2019 Mar 25. doi: 10.1002/pros.23797.
    PubMed     Abstract available


  263. KRZYZANOWSKA A, Don-Doncow N, Marginean FE, Gaber A, et al
    Expression of tSTAT3, pSTAT3(727) , and pSTAT3 (705) in the epithelial cells of hormone-naive prostate cancer.
    Prostate. 2019 Mar 24. doi: 10.1002/pros.23787.
    PubMed     Abstract available


  264. MILLIRON BJ, Bruneau M, Obeid E, Gross L, et al
    Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention.
    Prostate. 2019 Mar 24. doi: 10.1002/pros.23783.
    PubMed     Abstract available


  265. OH M, Alkhushaym N, Fallatah S, Althaghfi A, et al
    The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Prostate. 2019 Mar 22. doi: 10.1002/pros.23795.
    PubMed     Abstract available


  266. YUAN L, Huang X, Zhou K, Zhu X, et al
    Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
    Prostate. 2019 Mar 19. doi: 10.1002/pros.23788.
    PubMed     Abstract available


  267. JAGARLAMUDI KK, Zupan M, Kumer K, Fabjan T, et al
    The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
    Prostate. 2019 Mar 19. doi: 10.1002/pros.23791.
    PubMed     Abstract available


  268. SCHWEIZER MT, Gulati R, Beightol M, Konnick EQ, et al
    Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
    Prostate. 2019 Mar 13. doi: 10.1002/pros.23778.
    PubMed     Abstract available


  269. WANG X, Qi M, Zhang J, Sun X, et al
    Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Prostate. 2019 Mar 2. doi: 10.1002/pros.23777.
    PubMed     Abstract available


  270. ZHANG W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, et al
    Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    Prostate. 2019;79:390-402.
    PubMed     Abstract available


  271. PENG W, Guo L, Tang R, Liu X, et al
    Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer.
    Prostate. 2019;79:370-378.
    PubMed     Abstract available


    February 2019
  272. LEE SI, Roney MSI, Park JH, Baek JY, et al
    Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells.
    Prostate. 2019 Feb 28. doi: 10.1002/pros.23779.
    PubMed     Abstract available


  273. XUE YN, Yu BB, Liu YN, Guo R, et al
    Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
    Prostate. 2019 Feb 3. doi: 10.1002/pros.23772.
    PubMed     Abstract available


  274. XU Y, Song Q, Pascal LE, Zhong M, et al
    DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
    Prostate. 2019 Feb 3. doi: 10.1002/pros.23773.
    PubMed     Abstract available


  275. YU SH, Maynard JP, Vaghasia AM, De Marzo AM, et al
    A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.
    Prostate. 2019;79:215-222.
    PubMed     Abstract available


  276. KELLY NP, Flood HD, Hoey DA, Kiely PA, et al
    Direct mechanical characterization of prostate tissue-a systematic review.
    Prostate. 2019;79:115-125.
    PubMed     Abstract available


  277. MINNER S, Lutz J, Hube-Magg C, Kluth M, et al
    Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Prostate. 2019;79:302-311.
    PubMed     Abstract available


  278. SASAKI T, Franco OE, Ohishi K, Filipovich Y, et al
    Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
    Prostate. 2019;79:259-264.
    PubMed     Abstract available


  279. MEUNIER ME, Neuzillet Y, Raynaud JP, Radulescu C, et al
    Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial).
    Prostate. 2019;79:272-280.
    PubMed     Abstract available


    January 2019
  280. GAUR S, Gross ME, Liao CP, Qian B, et al
    Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Prostate. 2019 Jan 28. doi: 10.1002/pros.23774.
    PubMed     Abstract available


  281. CHOI YH, Han DH, Kim SW, Kim MJ, et al
    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.
    Prostate. 2019 Jan 22. doi: 10.1002/pros.23766.
    PubMed     Abstract available


  282. GHINEA N, Robin B, Pichon C, Leclere R, et al
    Vasa nervorum angiogenesis in prostate cancer with perineural invasion.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23771.
    PubMed     Abstract available


  283. LI C, He C, Xu Y, Xu H, et al
    Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23767.
    PubMed     Abstract available


  284. PETRYLAK DP, Kantoff P, Vogelzang NJ, Mega A, et al
    Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23765.
    PubMed     Abstract available


  285. JOENTAUSTA RM, Rannikko A, Murtola TJ
    Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
    Prostate. 2019 Jan 16. doi: 10.1002/pros.23768.
    PubMed     Abstract available


  286. LIU Y, Wu X, Jiang H
    Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23760.
    PubMed     Abstract available


  287. FAN L, Yang Y, Chi C, Ma X, et al
    Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23762.
    PubMed     Abstract available


  288. PAPANICOLAU-SENGOS A, Yang Y, Pabla S, Lenzo FL, et al
    Identification of targets for prostate cancer immunotherapy.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23756.
    PubMed     Abstract available


  289. HATANAKA Y, de Velasco MA, Oki T, Shimizu N, et al
    HOXA10 expression profiling in prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23761.
    PubMed     Abstract available


  290. ZHAO M, Qi M, Li X, Hu J, et al
    CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23754.
    PubMed     Abstract available


  291. BROADFIELD LA, Marcinko K, Tsakiridis E, Zacharidis PG, et al
    Salicylate enhances the response of prostate cancer to radiotherapy.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23755.
    PubMed     Abstract available


    December 2018
  292. TSUMURA H, Ishiyama H, Tabata KI, Sekiguchi A, et al
    Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
    Prostate. 2018 Dec 26. doi: 10.1002/pros.23757.
    PubMed     Abstract available


  293. MATEUS PAM, Kido LA, Silva RS, Cagnon VHA, et al
    Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Prostate. 2018 Dec 25. doi: 10.1002/pros.23758.
    PubMed     Abstract available


  294. DONADIO JLS, Liu L, Freeman VL, Ekoue DN, et al
    Interaction of NKX3.1 and SELENOP genotype with prostate cancer recurrence.
    Prostate. 2018 Dec 23. doi: 10.1002/pros.23752.
    PubMed     Abstract available


  295. IWAMOTO H, Izumi K, Natsagdorj A, Naito R, et al
    Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells.
    Prostate. 2018 Dec 19. doi: 10.1002/pros.23753.
    PubMed     Abstract available


  296. JOHNG D, Torga G, Ewing CM, Jin K, et al
    HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Prostate. 2018 Dec 17. doi: 10.1002/pros.23747.
    PubMed     Abstract available


  297. BARBAUD M, Frindel M, Ferrer L, Le Thiec M, et al
    68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Prostate. 2018 Dec 14. doi: 10.1002/pros.23751.
    PubMed     Abstract available


  298. ADAMO H, Hammarsten P, Hagglof C, Dahl Scherdin T, et al
    Prostate cancer induces C/EBPbeta expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.
    Prostate. 2018 Dec 11. doi: 10.1002/pros.23749.
    PubMed     Abstract available


  299. ZEDAN AH, Hansen TF, Assenholt J, Madsen JS, et al
    Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
    Prostate. 2018 Dec 9. doi: 10.1002/pros.23748.
    PubMed     Abstract available


    November 2018
  300. ERLANDSSON A, Carlsson J, Lundholm M, Falt A, et al
    M2 macrophages and regulatory T cells in lethal prostate cancer.
    Prostate. 2018 Nov 30. doi: 10.1002/pros.23742.
    PubMed     Abstract available


  301. MAJERA D, Skrott Z, Bouchal J, Bartkova J, et al
    Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
    Prostate. 2018 Nov 29. doi: 10.1002/pros.23741.
    PubMed     Abstract available


  302. KRUEGER TE, Thorek DLJ, Meeker AK, Isaacs JT, et al
    Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23738.
    PubMed     Abstract available


  303. COHEN M, Amir S, Golan M, Ben-Neriah Y, et al
    beta-TrCP upregulates HIF-1 in prostate cancer cells.
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23746.
    PubMed     Abstract available


  304. MIYAKE M, Tanaka N, Hori S, Ohnishi S, et al
    Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23740.
    PubMed     Abstract available


  305. GIRI VN, Hegarty SE, Hyatt C, O'Leary E, et al
    Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23739.
    PubMed     Abstract available


  306. ALANEE S, Holland B, Clemons J, Dynda D, et al
    Death due to sepsis in patients diagnosed with prostate cancer.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23735.
    PubMed     Abstract available


  307. GIULIANELLI R, Nardoni S, Bruzzese D, Falavolti C, et al
    Urotensin II receptor expression in prostate cancer patients: A new possible marker.
    Prostate. 2018 Nov 8. doi: 10.1002/pros.23734.
    PubMed     Abstract available


    October 2018
  308. MIYAHIRA AK, Den RB, Carlo MI, de Leeuw R, et al
    Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2018 Oct 31. doi: 10.1002/pros.23729.
    PubMed     Abstract available


  309. LAVOIE JM, Zou K, Khalaf D, Eigl BJ, et al
    Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
    Prostate. 2018 Oct 28. doi: 10.1002/pros.23733.
    PubMed     Abstract available


  310. SUER I, Guzel E, Karatas OF, Creighton CJ, et al
    MicroRNAs as prognostic markers in prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23731.
    PubMed     Abstract available


  311. ESKRA JN, Schlicht MJ, Bosland MC
    Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23727.
    PubMed     Abstract available


  312. KRANZBUHLER B, Salemi S, Mortezavi A, Sulser T, et al
    Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23725.
    PubMed     Abstract available


  313. SEKINO Y, Oue N, Mukai S, Shigematsu Y, et al
    Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Prostate. 2018 Oct 16. doi: 10.1002/pros.23728.
    PubMed     Abstract available


  314. ERYILMAZ IE, Aytac Vuruskan B, Kaygisiz O, Egeli U, et al
    RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
    Prostate. 2018 Oct 7. doi: 10.1002/pros.23724.
    PubMed     Abstract available


  315. WADOSKY KM, Shourideh M, Goodrich DW, Koochekpour S, et al
    Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.
    Prostate. 2018 Oct 2. doi: 10.1002/pros.23719.
    PubMed     Abstract available


    September 2018
  316. JAIN S, Dash P, Minz AP, Satpathi S, et al
    Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-kappaB activation and recurrent dexamethasone administration fails to suppress it in vivo.
    Prostate. 2018 Sep 27. doi: 10.1002/pros.23722.
    PubMed     Abstract available


  317. WANG J, Lu Z, Wu C, Li Y, et al
    Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23711.
    PubMed     Abstract available


  318. ROBERTO D, Klotz LH, Venkateswaran V
    Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23720.
    PubMed     Abstract available


  319. LIU J, Ding D, Jiang Z, Du T, et al
    Long non-coding RNA CCAT1/miR-148a/PKCzeta prevents cell migration of prostate cancer by altering macrophage polarization.
    Prostate. 2018 Sep 16. doi: 10.1002/pros.23716.
    PubMed     Abstract available


  320. GHORBANMEHR N, Gharbi S, Korsching E, Tavallaei M, et al
    miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
    Prostate. 2018 Sep 7. doi: 10.1002/pros.23714.
    PubMed     Abstract available


  321. CHEN Z, Jiang Q, Zhu P, Chen Y, et al
    NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Prostate. 2018 Sep 3. doi: 10.1002/pros.23709.
    PubMed     Abstract available


  322. DUGUE PA, Dowty JG, Joo JE, Wong EM, et al
    Heritable methylation marks associated with breast and prostate cancer risk.
    Prostate. 2018;78:962-969.
    PubMed     Abstract available


  323. VAN DUIJN PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, et al
    Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    Prostate. 2018;78:1013-1023.
    PubMed     Abstract available


    August 2018
  324. LI Y, Zhang Q, Lovnicki J, Chen R, et al
    SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23715.
    PubMed     Abstract available


  325. PALLER C, Pu H, Begemann DE, Wade CA, et al
    TGF-beta receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23708.
    PubMed     Abstract available


  326. XIE W, Stopsack KH, Drouin SJ, Fu H, et al
    Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23712.
    PubMed     Abstract available


  327. TOMMASI S, Pilato B, Carella C, Lasorella A, et al
    Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23710.
    PubMed     Abstract available


  328. ALANEE S, El-Zawahry A, Dynda D, Dabaja A, et al
    A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis.
    Prostate. 2018 Aug 16. doi: 10.1002/pros.23713.
    PubMed     Abstract available


  329. WEISSENRIEDER JS, Reilly JE, Neighbors JD, Hohl RJ, et al
    Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
    Prostate. 2018 Aug 14. doi: 10.1002/pros.23707.
    PubMed     Abstract available


  330. HUANG W, Su X, Yan W, Kong Z, et al
    Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
    Prostate. 2018 Aug 13. doi: 10.1002/pros.23700.
    PubMed     Abstract available


  331. CUI F, Hu J, Ning S, Tan J, et al
    Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
    Prostate. 2018 Aug 10. doi: 10.1002/pros.23703.
    PubMed     Abstract available


  332. GEVARIYA N, Besancon M, Robitaille K, Picard V, et al
    Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23706.
    PubMed     Abstract available


  333. NAVONE NM, van Weerden WM, Vessella RL, Williams ED, et al
    Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23701.
    PubMed     Abstract available


    July 2018
  334. CHAKRAVARTHI BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, et al
    Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23704.
    PubMed     Abstract available


  335. KOIDE H, Kimura T, Inaba H, Sato S, et al
    Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23705.
    PubMed     Abstract available


  336. WU Y, Yu H, Zheng SL, Feng B, et al
    Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
    Prostate. 2018 Jul 24. doi: 10.1002/pros.23697.
    PubMed     Abstract available


  337. LIU C, Zhu Y, Su H, Xu X, et al
    Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23696.
    PubMed     Abstract available


  338. YAMAKAWA T, Waer C, Itakura K
    AT-rich interactive domain 5B regulates androgen receptor transcription in human prostate cancer cells.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23699.
    PubMed     Abstract available


  339. ROOT A, Ebhardt HA
    A two-drug combination simulation study for metastatic castrate resistant prostate cancer.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23694.
    PubMed     Abstract available


  340. YANG T, Jing Y, Dong J, Yu X, et al
    Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23695.
    PubMed     Abstract available


  341. HE W, Li J
    Exendin-4 enhances radiation response of prostate cancer.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23687.
    PubMed     Abstract available


  342. LI D, Tian G, Wang J, Zhao LY, et al
    Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23689.
    PubMed     Abstract available


  343. DORAI T, Shah A, Summers F, Mathew R, et al
    NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23693.
    PubMed     Abstract available


  344. TWEEDLE MF, Ding H, Drost WT, Dowell J, et al
    Development of an orthotopic canine prostate cancer model expressing human GRPr.
    Prostate. 2018 Jul 11. doi: 10.1002/pros.23686.
    PubMed     Abstract available


  345. LIM DM, Gulati R, Aleshin-Guendel S, Gawne A, et al
    Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival.
    Prostate. 2018 Jul 10. doi: 10.1002/pros.23666.
    PubMed     Abstract available


  346. ROGASCH JM, Cash H, Zschaeck S, Elezkurtaj S, et al
    Ga-68-PSMA PET/CT in treatment-naive patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
    Prostate. 2018 Jul 5. doi: 10.1002/pros.23685.
    PubMed     Abstract available


    June 2018
  347. ZHAO S, Leonardson A, Geybels MS, McDaniel AS, et al
    A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.
    Prostate. 2018 Jun 28. doi: 10.1002/pros.23667.
    PubMed     Abstract available


  348. COOK SF, Fiandalo MV, Watt DS, Wu Y, et al
    Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.
    Prostate. 2018 Jun 25. doi: 10.1002/pros.23665.
    PubMed     Abstract available


  349. HELFAND BT, Chen H, Fantus RJ, Conran CA, et al
    Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
    Prostate. 2018 Jun 19. doi: 10.1002/pros.23664.
    PubMed     Abstract available


  350. BARATA P, Emamekhoo H, Mendiratta P, Koshkin V, et al
    Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23663.
    PubMed     Abstract available


  351. CHOUDHURY AD, Gray KP, Supko JG, Harshman LC, et al
    A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23662.
    PubMed     Abstract available


  352. CHAKRAVARTHI BVSK, Goswami MT, Pathi SS, Dodson M, et al
    Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.
    Prostate. 2018;78:693-694.
    PubMed    


  353. FURRER MA, Vilaseca A, Corradi RB, Boxler S, et al
    Repeat prostate biopsies prior to radical prostatectomy do not impact erectile function recovery and mid- to long-term continence.
    Prostate. 2018;78:631-636.
    PubMed     Abstract available


  354. THOMAS-JARDIN SE, Kanchwala MS, Jacob J, Merchant S, et al
    Identification of an IL-1-induced gene expression pattern in AR(+) PCa cells that mimics the molecular phenotype of AR(-) PCa cells.
    Prostate. 2018;78:595-606.
    PubMed     Abstract available


  355. OJALILL M, Rappu P, Siljamaki E, Taimen P, et al
    The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis.
    Prostate. 2018;78:583-594.
    PubMed     Abstract available


    May 2018
  356. MIYAHIRA AK, Soule HR
    The 24th Annual Prostate Cancer Foundation scientific retreat report.
    Prostate. 2018 May 15. doi: 10.1002/pros.23651.
    PubMed     Abstract available


  357. AL SALEH HA, Haas-Neill S, Al-Hashimi A, Kapoor A, et al
    Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
    Prostate. 2018 May 15. doi: 10.1002/pros.23653.
    PubMed     Abstract available


  358. JARVIS C, Nelius T, Martinez-Marin D, Sennoune SR, et al
    Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Prostate. 2018 May 10. doi: 10.1002/pros.23647.
    PubMed     Abstract available


  359. MUNOZ-MORENO L, Schally AV, Prieto JC, Carmena MJ, et al
    Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23648.
    PubMed     Abstract available


  360. TINAY I, Tan M, Gui B, Werner L, et al
    Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23650.
    PubMed     Abstract available


  361. ALLOTT EH, Farnan L, Steck SE, Song L, et al
    Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.
    Prostate. 2018 May 1. doi: 10.1002/pros.23644.
    PubMed     Abstract available


  362. MIYAHIRA AK, Pienta KJ, Morris MJ, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
    Prostate. 2018 May 1. doi: 10.1002/pros.23642.
    PubMed     Abstract available


  363. CAMPOLINA-SILVA GH, Maria BT, Mahecha GAB, Oliveira CA, et al
    Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions.
    Prostate. 2018;78:532-546.
    PubMed     Abstract available


    April 2018
  364. ISHII K, Sasaki T, Iguchi K, Kajiwara S, et al
    Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23643.
    PubMed     Abstract available


  365. FRANCINI E, Gray KP, Xie W, Shaw GK, et al
    Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23645.
    PubMed     Abstract available


  366. BEYENE DA, Naab TJ, Kanarek NF, Apprey V, et al
    Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
    Prostate. 2018 Apr 22. doi: 10.1002/pros.23537.
    PubMed     Abstract available


  367. BAYAT H, Narouie B, Ziaee SM, Mowla SJ, et al
    Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
    Prostate. 2018 Apr 19. doi: 10.1002/pros.23538.
    PubMed     Abstract available


  368. MILLER EA, Pinsky PF, Black A, Andriole GL, et al
    Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Prostate. 2018 Apr 17. doi: 10.1002/pros.23540.
    PubMed     Abstract available


  369. POMPE RS, Tilki D, Preisser F, Leyh-Bannurah SR, et al
    Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23519.
    PubMed     Abstract available


  370. KOSTOVA MB, Brennen WN, Lopez D, Anthony L, et al
    PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23539.
    PubMed     Abstract available


  371. GIRI VN, Obeid E, Hegarty SE, Gross L, et al
    Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
    Prostate. 2018 Apr 14. doi: 10.1002/pros.23535.
    PubMed     Abstract available


  372. MORI K, Kimura T, Ito K, Onuma H, et al
    Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Prostate. 2018 Apr 10. doi: 10.1002/pros.23534.
    PubMed     Abstract available


  373. BRATT O
    RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23520.
    PubMed    


  374. KRANZBUHLER B, Salemi S, Umbricht CA, Muller C, et al
    Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23522.
    PubMed     Abstract available


  375. PRENCIPE M, Fabre A, Murphy TB, Vargyas E, et al
    Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23516.
    PubMed     Abstract available


  376. PREISSER F, Bandini M, Graefen M, Tilki D, et al
    Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
    Prostate. 2018 Apr 2. doi: 10.1002/pros.23521.
    PubMed    


    March 2018
  377. GAO X, Mao YH, Xiao C, Li K, et al
    Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway.
    Prostate. 2018 Mar 30. doi: 10.1002/pros.23512.
    PubMed     Abstract available


  378. BABCOOK MA, Akgul M, Margevicius S, MacLennan GT, et al
    Ser-486/491 phosphorylation and inhibition of AMPKalpha activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
    Prostate. 2018 Mar 26. doi: 10.1002/pros.23515.
    PubMed     Abstract available


  379. BRENNEN WN, Isaacs JT
    The what, when, and why of human prostate cancer xenografts.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23510.
    PubMed     Abstract available


  380. LINXWEILER J, Korbel C, Muller A, Hammer M, et al
    A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23508.
    PubMed     Abstract available


  381. AKINBOYE ES, Rogers OC, Isaacs JT
    2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
    Prostate. 2018 Mar 24. doi: 10.1002/pros.23494.
    PubMed     Abstract available


  382. CAMPOS C, Sotomayor P, Jerez D, Gonzalez J, et al
    Exercise and prostate cancer: From basic science to clinical applications.
    Prostate. 2018 Mar 23. doi: 10.1002/pros.23502.
    PubMed     Abstract available


  383. CHEN J, Oromendia C, Halpern JA, Ballman KV, et al
    National trends in management of localized prostate cancer: A population based analysis 2004-2013.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23496.
    PubMed     Abstract available


  384. WANG Y, Xu H, Si L, Li Q, et al
    MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23468.
    PubMed     Abstract available


  385. DAVID SN, Arnold Egloff SA, Goyal R, Clark PE, et al
    MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
    Prostate. 2018 Mar 14. doi: 10.1002/pros.23506.
    PubMed     Abstract available


  386. CARLETON NM, Zhu G, Gorbounov M, Miller MC, et al
    PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23499.
    PubMed     Abstract available


  387. KEAM SP, Gulati T, Gamell C, Caramia F, et al
    Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23500.
    PubMed     Abstract available


  388. HAYMAN J, Phillips R, Chen D, Perin J, et al
    Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23507.
    PubMed     Abstract available


  389. WU Y, Yu H, Zheng SL, Na R, et al
    A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23505.
    PubMed     Abstract available


  390. OKEGAWA T, Ninomiya N, Masuda K, Nakamura Y, et al
    AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Prostate. 2018 Mar 5. doi: 10.1002/pros.23501.
    PubMed     Abstract available


  391. BERGSTROM SH, Jaremo H, Nilsson M, Adamo HH, et al
    Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
    Prostate. 2018;78:257-265.
    PubMed     Abstract available


    February 2018
  392. COPELAND BT, Pal SK, Bolton EC, Jones JO, et al
    The androgen receptor malignancy shift in prostate cancer.
    Prostate. 2018 Feb 23. doi: 10.1002/pros.23497.
    PubMed     Abstract available


  393. ITO K, Kimura T, Onuma H, Tabata R, et al
    Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Prostate. 2018 Feb 23. doi: 10.1002/pros.23493.
    PubMed     Abstract available


  394. MACCINI MA, Westfall NJ, Van Bokhoven A, Lucia MS, et al
    The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
    Prostate. 2018 Feb 19. doi: 10.1002/pros.23495.
    PubMed     Abstract available


  395. PREISSER F, Bandini M, Marchioni M, Nazzani S, et al
    Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Prostate. 2018 Feb 19. doi: 10.1002/pros.23491.
    PubMed     Abstract available


  396. SHOU J, Zhang Q, Wang S, Zhang D, et al
    The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
    Prostate. 2018 Feb 13. doi: 10.1002/pros.23492.
    PubMed     Abstract available


  397. DE LAERE B, Oeyen S, Van Oyen P, Ghysel C, et al
    Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    Prostate. 2018 Feb 12. doi: 10.1002/pros.23488.
    PubMed     Abstract available


  398. SILVA JAF, Bruni-Cardoso A, Augusto TM, Damas-Souza DM, et al
    Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration.
    Prostate. 2018;78:95-103.
    PubMed     Abstract available


  399. RODRIGO MAM, Strmiska V, Horackova E, Buchtelova H, et al
    Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes.
    Prostate. 2018;78:104-112.
    PubMed     Abstract available


  400. PAZIEWSKA A, Mikula M, Dabrowska M, Kulecka M, et al
    Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
    Prostate. 2018;78:178-185.
    PubMed     Abstract available


    January 2018
  401. JIANG X, Huang Y, Liang X, Jiang F, et al
    Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
    Prostate. 2018 Jan 31. doi: 10.1002/pros.23487.
    PubMed     Abstract available


  402. KARLSSON T, Sundar R, Widmark A, Landstrom M, et al
    Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor beta (TGFbeta) signaling.
    Prostate. 2018 Jan 31. doi: 10.1002/pros.23489.
    PubMed     Abstract available


  403. MCDONALD AC, Vira M, Shen J, Sanda M, et al
    Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
    Prostate. 2018 Jan 31. doi: 10.1002/pros.23485.
    PubMed     Abstract available


  404. WANG L, Kim D, Wise JTF, Shi X, et al
    p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23483.
    PubMed     Abstract available


  405. WURNSCHIMMEL C, Grande P, Moschini M, Ferrari M, et al
    Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23480.
    PubMed     Abstract available


  406. ISAACSSON VELHO P, Silberstein JL, Markowski MC, Luo J, et al
    Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23484.
    PubMed     Abstract available


  407. MIKI J, Yanagisawa T, Tsuzuki S, Mori K, et al
    Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer.
    Prostate. 2018 Jan 25. doi: 10.1002/pros.23486.
    PubMed     Abstract available


  408. DU Z, Lubmawa A, Gundell S, Wan P, et al
    Genetic risk of prostate cancer in ugandan men.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23481.
    PubMed     Abstract available


  409. BEEBE-DIMMER JL, Zuhlke KA, Johnson AM, Liesman D, et al
    Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23464.
    PubMed     Abstract available


  410. HUANG H, Wang Q, Du T, Lin C, et al
    Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.
    Prostate. 2018 Jan 21. doi: 10.1002/pros.23469.
    PubMed     Abstract available


  411. SU Z, Zhang M, Xu M, Li X, et al
    MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
    Prostate. 2018 Jan 16. doi: 10.1002/pros.23478.
    PubMed     Abstract available


  412. KIMBROUGH-ALLAH MN, Millena AC, Khan SA
    Differential role of PTEN in transforming growth factor beta (TGF-beta) effects on proliferation and migration in prostate cancer cells.
    Prostate. 2018 Jan 16. doi: 10.1002/pros.23482.
    PubMed     Abstract available


  413. HENDRIKS RJ, Dijkstra S, Smit FP, Vandersmissen J, et al
    Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
    Prostate. 2018 Jan 12. doi: 10.1002/pros.23477.
    PubMed     Abstract available


  414. XU L, Shen M, Chen X, Zhu R, et al
    Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Prostate. 2018 Jan 12. doi: 10.1002/pros.23479.
    PubMed     Abstract available


  415. AZUMA T
    Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
    Prostate. 2018 Jan 8. doi: 10.1002/pros.23470.
    PubMed    


  416. ALBITAR M, Ma W, Lund L, Shahbaba B, et al
    Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
    Prostate. 2018 Jan 8. doi: 10.1002/pros.23473.
    PubMed     Abstract available


  417. EKOUE DN, Ansong E, Liu L, Macias V, et al
    Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
    Prostate. 2018 Jan 5. doi: 10.1002/pros.23471.
    PubMed     Abstract available


  418. LIN HM, Lee BY, Castillo L, Spielman C, et al
    Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Prostate. 2018 Jan 5. doi: 10.1002/pros.23476.
    PubMed     Abstract available


  419. TYAGI P, Motley SS, Koyama T, Kashyap M, et al
    Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.
    Prostate. 2018;78:17-24.
    PubMed     Abstract available


    December 2017
  420. VAN DER TOOM EE, Groot VP, Glavaris SA, Gemenetzis G, et al
    Analogous detection of circulating tumor cells using the AccuCyte((R)) -CyteFinder((R)) system and ISET system in patients with locally advanced and metastatic prostate cancer.
    Prostate. 2017 Dec 29. doi: 10.1002/pros.23474.
    PubMed     Abstract available


  421. FAN L, Wang R, Chi C, Cai W, et al
    Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Prostate. 2017 Dec 29. doi: 10.1002/pros.23465.
    PubMed     Abstract available


  422. MCLEOD AB, Stice JP, Wardell SE, Alley HM, et al
    Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    Prostate. 2017 Dec 15. doi: 10.1002/pros.23467.
    PubMed     Abstract available


  423. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
    Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
    Prostate. 2017;77:1592-1600.
    PubMed     Abstract available


  424. ZHOU CK, Stanczyk FZ, Hafi M, Veneroso CC, et al
    Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
    Prostate. 2017;77:1573-1582.
    PubMed     Abstract available


  425. BAUER SR, Van Blarigan EL, Stampfer MJ, Chan JM, et al
    Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study.
    Prostate. 2017 Dec 1. doi: 10.1002/pros.23457.
    PubMed     Abstract available


  426. ANDO T, Nishiyama T, Takizawa I, Miyashiro Y, et al
    A carbon 21 steroidal metabolite from progestin, 20beta-hydroxy-5alpha-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
    Prostate. 2017 Dec 1. doi: 10.1002/pros.23460.
    PubMed     Abstract available


  427. FIANDALO MV, Wilton JH, Mantione KM, Wrzosek C, et al
    Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
    Prostate. 2017 Dec 1. doi: 10.1002/pros.23459.
    PubMed     Abstract available


    November 2017
  428. YAN G, Ru Y, Wu K, Yan F, et al
    GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Prostate. 2017 Nov 27. doi: 10.1002/pros.23461.
    PubMed     Abstract available


  429. CHEN H, Ewing CM, Zheng S, Grindedaal EM, et al
    Genetic factors influencing prostate cancer risk in Norwegian men.
    Prostate. 2017 Nov 27. doi: 10.1002/pros.23453.
    PubMed     Abstract available


  430. JOSHU CE, Peskoe SB, Heaphy CM, Kenfield SA, et al
    Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.
    Prostate. 2017 Nov 22. doi: 10.1002/pros.23462.
    PubMed     Abstract available


  431. TSUI KH, Chang YL, Feng TH, Hou CP, et al
    Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
    Prostate. 2017 Nov 22. doi: 10.1002/pros.23463.
    PubMed     Abstract available


  432. FACINA CH, Campos SGP, Goncalves BF, Goes RM, et al
    Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer.
    Prostate. 2017 Nov 17. doi: 10.1002/pros.23458.
    PubMed     Abstract available


  433. GHASHGHAEI M, Paliouras M, Heravi M, Bekerat H, et al
    Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Prostate. 2017 Nov 14. doi: 10.1002/pros.23445.
    PubMed     Abstract available


  434. KALSBEEK AMF, Chan EKF, Grogan J, Petersen DC, et al
    Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
    Prostate. 2017 Nov 14. doi: 10.1002/pros.23440.
    PubMed     Abstract available


  435. COARFA C, Florentin D, Putluri N, Ding Y, et al
    Influence of the neural microenvironment on prostate cancer.
    Prostate. 2017 Nov 13. doi: 10.1002/pros.23454.
    PubMed     Abstract available


  436. TAT D, Kenfield SA, Cowan JE, Broering JM, et al
    Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE).
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23441.
    PubMed     Abstract available


  437. MARTINO T, Kudrolli TA, Kumar B, Salviano I, et al
    The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23455.
    PubMed     Abstract available


  438. CHENG HH, Plets M, Li H, Higano CS, et al
    Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23452.
    PubMed     Abstract available


  439. XIAO H, Wang J, Yan W, Cui Y, et al
    GLUT1 regulates cell glycolysis and proliferation in prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23448.
    PubMed     Abstract available


  440. SCHMIDKONZ C, Hollweg C, Beck M, Reinfelder J, et al
    99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23444.
    PubMed     Abstract available


  441. DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
    FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
    Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
    PubMed     Abstract available


  442. BONKHOFF H
    Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23446.
    PubMed     Abstract available


  443. KATO M, Kimura K, Hirakawa A, Kobayashi Y, et al
    Prognostic parameter for high risk prostate cancer patients at initial presentation.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23438.
    PubMed     Abstract available


  444. TJON-KON-FAT LA, Lundholm M, Schroder M, Wurdinger T, et al
    Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
    Prostate. 2017 Nov 2. doi: 10.1002/pros.23443.
    PubMed     Abstract available


  445. NESBITT H, Worthington J, Errington RJ, Patterson LH, et al
    The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
    Prostate. 2017;77:1539-1547.
    PubMed     Abstract available


    October 2017
  446. STARK TW, Hensley PJ, Spear A, Pu H, et al
    Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
    Prostate. 2017 Oct 23. doi: 10.1002/pros.23435.
    PubMed     Abstract available


  447. WOODS-BURNHAM L, Basu A, Cajigas-Du Ross CK, Love A, et al
    The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
    Prostate. 2017 Oct 14. doi: 10.1002/pros.23437.
    PubMed     Abstract available


  448. LI E, Liu L, Li F, Luo L, et al
    PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
    Prostate. 2017 Oct 2. doi: 10.1002/pros.23432.
    PubMed     Abstract available


  449. ABEDINPOUR P, Baron VT, Chrastina A, Rondeau G, et al
    Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
    Prostate. 2017 Oct 2. doi: 10.1002/pros.23428.
    PubMed     Abstract available


  450. SHI X, Peng Y, Du X, Liu H, et al
    Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.
    Prostate. 2017;77:1424-1437.
    PubMed     Abstract available


  451. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
    Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
    Prostate. 2017;77:1383-1388.
    PubMed     Abstract available


    September 2017
  452. BURDELSKI C, Shihada R, Hinsch A, Angerer A, et al
    High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
    Prostate. 2017 Sep 19. doi: 10.1002/pros.23431.
    PubMed     Abstract available


  453. MIYAHIRA AK, Cheng HH, Abida W, Ellis L, et al
    Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2017 Sep 18. doi: 10.1002/pros.23424.
    PubMed     Abstract available


  454. TSUMURA H, Ishiyama H, Tabata KI, Katsumata H, et al
    Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23430.
    PubMed     Abstract available


  455. KANAYAMA M, Hayano T, Koebis M, Maeda T, et al
    Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23425.
    PubMed     Abstract available


  456. PEDRAZA-AREVALO S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, et al
    Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23426.
    PubMed     Abstract available


  457. STROMVALL K, Sundkvist K, Ljungberg B, Halin Bergstrom S, et al
    Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
    Prostate. 2017 Sep 7. doi: 10.1002/pros.23407.
    PubMed     Abstract available


  458. YANG CS, Melhuish TA, Spencer A, Ni L, et al
    The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
    Prostate. 2017 Sep 6. doi: 10.1002/pros.23400.
    PubMed     Abstract available


  459. VINCENEUX A, Bruyere F, Haillot O, Charles T, et al
    Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
    Prostate. 2017;77:1242-1250.
    PubMed     Abstract available


    August 2017
  460. GINSBURG KB, Elshafei A, Yu C, Jones JS, et al
    Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23406.
    PubMed     Abstract available


  461. SOEKMADJI C, Corcoran NM, Oleinikova I, Jovanovic L, et al
    Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23403.
    PubMed     Abstract available


  462. HENDRIKS RJ, van der Leest MMG, Dijkstra S, Barentsz JO, et al
    A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23401.
    PubMed     Abstract available


  463. SUH JH, Park JH, Lee C, Moon KC, et al
    Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23405.
    PubMed     Abstract available


  464. LIU L, Li E, Luo L, Zhao S, et al
    PSCA regulates IL-6 expression through p38/NF-kappaB signaling in prostate cancer.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23399.
    PubMed     Abstract available


  465. MIYATA Y, Nakamura Y, Yasuda T, Matsuo T, et al
    Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23402.
    PubMed     Abstract available


  466. DONG B, Fan L, Wang Y, Chi C, et al
    Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
    Prostate. 2017 Aug 14. doi: 10.1002/pros.23397.
    PubMed     Abstract available


  467. STRUSS WJ, Tan Z, Zachkani P, Moskalev I, et al
    Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.
    Prostate. 2017 Aug 8. doi: 10.1002/pros.23395.
    PubMed     Abstract available


  468. PALLER CJ, Cole AP, Partin AW, Carducci MA, et al
    Risk factors for metastatic prostate cancer: A sentinel event case series.
    Prostate. 2017 Aug 8. doi: 10.1002/pros.23396.
    PubMed     Abstract available


  469. VAN NESTE L, Groskopf J, Grizzle WE, Adams GW, et al
    Epigenetic risk score improves prostate cancer risk assessment.
    Prostate. 2017 Aug 1. doi: 10.1002/pros.23385.
    PubMed     Abstract available


  470. HARSHMAN LC, Werner L, Tripathi A, Wang X, et al
    The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
    Prostate. 2017 Aug 1. doi: 10.1002/pros.23390.
    PubMed     Abstract available


    July 2017
  471. FAN L, Wang X, Chi C, Wang Y, et al
    Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2017 Jul 28. doi: 10.1002/pros.23381.
    PubMed     Abstract available


  472. SUN G, Huang R, Zhang X, Shen P, et al
    The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.
    Prostate. 2017 Jul 27. doi: 10.1002/pros.23388.
    PubMed     Abstract available


  473. SHARPE B, Alghezi DA, Cattermole C, Beresford M, et al
    A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
    Prostate. 2017 Jul 26. doi: 10.1002/pros.23391.
    PubMed     Abstract available


  474. LIN X, Chen Z, Gao P, Gao Z, et al
    TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.
    Prostate. 2017 Jul 21. doi: 10.1002/pros.23387.
    PubMed     Abstract available


  475. AI J, Tai PWL, Lu Y, Li J, et al
    Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.
    Prostate. 2017 Jul 20. doi: 10.1002/pros.23386.
    PubMed     Abstract available


  476. TODENHOFER T, Hennenlotter J, Keller G, Neumann T, et al
    Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.
    Prostate. 2017 Jul 20. doi: 10.1002/pros.23384.
    PubMed     Abstract available


  477. BREEN KJ, O'Neill A, Murphy L, Fan Y, et al
    Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
    Prostate. 2017 Jul 20. doi: 10.1002/pros.23389.
    PubMed     Abstract available


  478. CHEN H, Na R, Packiam VT, Conran CA, et al
    Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
    Prostate. 2017 Jul 2. doi: 10.1002/pros.23369.
    PubMed     Abstract available


  479. DE BARI B, Stish B, Ball MW, Habboush Y, et al
    Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.
    Prostate. 2017;77:1160-1166.
    PubMed     Abstract available


  480. RODRIGUES TM, Mitre AI, da Silva LFF, Castilho LN, et al
    Periprostatic innervation: New issues based on segmental analysis of 10 human cadaver pelvic blocs.
    Prostate. 2017;77:1151-1159.
    PubMed     Abstract available


  481. BOKHORST LP, Roobol MJ, Bangma CH, van Leenders GJ, et al
    Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
    Prostate. 2017;77:1137-1143.
    PubMed     Abstract available


    June 2017
  482. LAWAL IO, Ankrah AO, Mokgoro NP, Vorster M, et al
    Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Prostate. 2017 Jun 26. doi: 10.1002/pros.23379.
    PubMed     Abstract available


  483. CRUMBAKER M, Gurney H
    Dose considerations for anti-cancer drugs in metastatic prostate cancer.
    Prostate. 2017 Jun 26. doi: 10.1002/pros.23378.
    PubMed     Abstract available


  484. HE C, Duan S, Dong L, Wang Y, et al
    Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
    PubMed     Abstract available


  485. CAI B, Chen W, Pan Y, Chen H, et al
    Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
    Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
    PubMed     Abstract available


  486. XU Y, Qin S, An T, Tang Y, et al
    MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
    Prostate. 2017 Jun 15. doi: 10.1002/pros.23376.
    PubMed     Abstract available


  487. ZHAO R, Sun F, Bei X, Wang X, et al
    Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
    Prostate. 2017 Jun 6. doi: 10.1002/pros.23367.
    PubMed     Abstract available


  488. ARMSTRONG CM, Liu C, Lou W, Lombard AP, et al
    MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
    Prostate. 2017;77:1020-1028.
    PubMed     Abstract available


  489. GONZAGA ACR, Campolina-Silva GH, Werneck-Gomes H, Moura-Cordeiro JD, et al
    Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats.
    Prostate. 2017;77:937-948.
    PubMed     Abstract available


  490. AJIBOYE AS, Esopi D, Yegnasubramanian S, Denmeade SR, et al
    Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
    Prostate. 2017;77:829-837.
    PubMed     Abstract available


  491. KIDO LA, Montico F, Vendramini-Costa DB, Pilli RA, et al
    Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
    Prostate. 2017;77:838-848.
    PubMed     Abstract available


  492. SHARIF A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, et al
    The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
    Prostate. 2017;77:824-828.
    PubMed     Abstract available


    May 2017
  493. MORI K, Kimura T, Onuma H, Kimura S, et al
    Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
    Prostate. 2017 May 30. doi: 10.1002/pros.23373.
    PubMed     Abstract available


  494. KIM Y, Park SE, Moon JW, Kim BM, et al
    Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer.
    Prostate. 2017 May 30. doi: 10.1002/pros.23370.
    PubMed     Abstract available


  495. NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
    Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
    Prostate. 2017 May 26. doi: 10.1002/pros.23364.
    PubMed     Abstract available


  496. IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
    Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
    Prostate. 2017 May 24. doi: 10.1002/pros.23368.
    PubMed     Abstract available


  497. MIYAHIRA AK, Soule HR
    The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2017 May 14. doi: 10.1002/pros.23366.
    PubMed     Abstract available


  498. NOVAKOVA Z, Foss CA, Copeland BT, Morath V, et al
    Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
    Prostate. 2017;77:749-764.
    PubMed     Abstract available


  499. HUANG H, Du T, Zhang Y, Lai Y, et al
    Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.
    Prostate. 2017;77:718-728.
    PubMed     Abstract available


  500. OLSON BM, Bradley ES, Sawicki T, Zhong W, et al
    Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).
    Prostate. 2017;77:812-821.
    PubMed     Abstract available


  501. POMPE RS, Davis-Bondarenko H, Zaffuto E, Tian Z, et al
    Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
    Prostate. 2017;77:686-693.
    PubMed     Abstract available


  502. MELITI A, Sadimin E, Diolombi M, Khani F, et al
    Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors.
    Prostate. 2017;77:681-685.
    PubMed     Abstract available


  503. PIERCONTI F, Martini M, Cenci T, Petrone GL, et al
    SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Prostate. 2017;77:597-603.
    PubMed     Abstract available


  504. HENNING JD, Karamchandani JM, Bonachea LA, Bunker CH, et al
    Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago.
    Prostate. 2017;77:617-624.
    PubMed     Abstract available


  505. BRETT SI, Lucien F, Guo C, Williams KC, et al
    Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples.
    Prostate. 2017;77:1335-1343.
    PubMed     Abstract available


    April 2017
  506. SCHALLY AV, Block NL, Rick FG
    Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
    Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
    PubMed     Abstract available


  507. CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
    Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
    PubMed     Abstract available


  508. JIA L, Gui B, Zheng D, Decker KF, et al
    Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
    PubMed     Abstract available


  509. TANG B, Han CT, Gan HL, Zhang GM, et al
    Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
    PubMed     Abstract available


  510. PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
    Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
    PubMed     Abstract available


  511. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
    When should active surveillance for prostate cancer stop if no progression is detected?
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
    PubMed     Abstract available


  512. GONCALVES BF, de Campos SG, Goes RM, Scarano WR, et al
    Dual action of high estradiol doses on MNU-induced prostate neoplasms in a rodent model with high serum testosterone: Protective effect and emergence of unstable epithelial microenvironment.
    Prostate. 2017 Apr 12. doi: 10.1002/pros.23353.
    PubMed     Abstract available


  513. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
    Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
    PubMed     Abstract available


  514. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
    External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
    Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
    PubMed     Abstract available


    March 2017
  515. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
    Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
    Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
    PubMed     Abstract available


  516. HABL G, Sauter K, Schiller K, Dewes S, et al
    68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
    PubMed     Abstract available


  517. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
    Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
    PubMed     Abstract available


  518. TOLKACH Y, Eminaga O, Wotzel F, Huss S, et al
    Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.
    Prostate. 2017;77:396-405.
    PubMed     Abstract available


    November 2016
  519. REGIS L, Planas J, Carles J, Maldonado X, et al
    Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
    Prostate. 2016 Nov 1. doi: 10.1002/pros.23256.
    PubMed     Abstract available


    July 2016
  520. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
    Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
    Prostate. 2016;76:917-26.
    PubMed     Abstract available


  521. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
    Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Prostate. 2016;76:905-16.
    PubMed     Abstract available


    June 2016
  522. GERRIN SJ, Sowalsky AG, Balk SP, Ye H, et al
    Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23212.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: